Search Results - "Geiger, Jessica Lyn"

Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma by Brito, Karina, Fan, Cong, Miller, Jacob, Campbell, Shauna, Silver, Natalie L., McGrail, Daniel, Ku, Jamie, Lamarre, Eric, Yilmaz, Emrullah, Sussman, Tamara A., Geiger, Jessica Lyn, Koyfman, Shlomo A.

“…9585 Background: Neoadjuvant immunotherapy is a potential curative approach to patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that…”
Get full text

A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck by Harrington, Kevin Joseph, Cohen, Ezra, Zandberg, Dan Paul, Day, Terry A., Geiger, Jessica Lyn, Oliva, Marc, Mesia, Ricard, Cohan, David Michael

“…TPS6106 Background: Head and neck (HN) cancers were estimated to account for > 50,000 new cancer diagnoses and > 11,000 deaths in the US in 2022. Squamous cell…”
Get full text

Patterns and outcomes of palliative radiation therapy with immunotherapy in locally recurrent head and neck squamous cell carcinoma by Roof, Logan, Buchberger, David, Yalamanchali, Anirudh, Campbell, Shauna, Miller, Jacob, Koyfman, Shlomo A., Woody, Neil McIver, Geiger, Jessica Lyn, Yilmaz, Emrullah

“…e18015 Background: Immune checkpoint inhibitors (ICI) have been shown to improve outcomes in patients with recurrent or metastatic (R/M) head and neck squamous…”
Get full text

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202 by Swiecicki, Paul, Yilmaz, Emrullah, Rosenberg, Ari J., Fujisawa, Takao, Yang Bruce, Justine, Meng, Changting, Wozniak, Michele, Wang, Lu, Gorla, Seema Rao, Geiger, Jessica Lyn

“…6017 Background: Globally, HNCs accounted for an estimated 932,000 new cases and 467,000 deaths in 2020. Nectin-4 is expressed in a majority of HNCs. Given the…”
Get full text

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial by Honma, Yoshitaka, Swiecicki, Paul L., Rosenberg, Ari Joseph, Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Muro, Kei, Kaplan, Jason B., Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn

“…TPS148 Background: Novel treatment strategies are needed to treat recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) given the poor…”
Get full text

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial by Swiecicki, Paul, Rosenberg, Ari J., Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Honma, Yoshitaka, Muro, Kei, Kaplan, Jason, Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn

“…TPS6116 Background: Novel treatment strategies are needed to treat recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) given the poor…”
Get full text

Evaluating the impact of the degree of extranodal extension on outcomes in locally advanced oral cavity cancer by Yalamanchali, Anirudh, Griffith, Christopher, Reddy, Chandana A., Koyfman, Shlomo A., Woody, Neil McIver, Campbell, Shauna, Silver, Natalie L., Scharpf, Joseph, Lorenz, Robert R, Prendes, Brandon, Ku, Jamie, Lamarre, Eric, Geiger, Jessica Lyn

“…e18058 Background: The presence of extranodal extension (ENE) in oral cavity cancer is associated with a higher risk of distant metastasis and worse overall…”
Get full text

Factors associated with recurrence and death in patients with aggressive hobnail morphology papillary thyroid carcinoma by Sharrett, Jonathan Matthew, Li, Hong, Shah, Akeesha, Nasr, Christian, Scharpf, Joseph, Koyfman, Shlomo A., Joshi, Nikhil, Geiger, Jessica Lyn

“…Abstract only e17590 Background: Papillary thyroid carcinoma (PTC) with hobnail morphology (HM) is an aggressive variant associated with poorer outcomes…”
Get full text

Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience by Kuzmanovic, Teodora, Horvath, Donna, Slaughter, Maurice, Karasik, Natalya, Bosler, David, Moore, Halle C. F., Abraham, Jame, Geiger, Jessica Lyn, Funchain, Pauline, Gerds, Aaron Thomas, Advani, Anjali S., Mukherjee, Sudipto, Molina, John Carlos, Balderman, Sophia Rebecca, Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Bolwell, Brian James, Carraway, Hetty E, Patel, Bhumika J, Singh, Abhay

“…7010 Background: Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is found in healthy populations as well as cancer patients (pts) and is associated…”
Get full text

Immunotherapy response in patients with cutaneous squamous cell carcinoma of head and neck with cranial nerve involvement by Lopetegui‐Lia, Nerea, Dima, Danai, Buchberger, David Scott, Yalamanchali, Anirudh, Osantowski, Bennett, Ondeck, Mariah, Lorenz, Robert Roman, Prendes, Brandon, Ku, Jamie, Lamarre, Eric, Scharpf, Joseph, Silver, Natalie Lea, Schwartzman, Larisa, Geiger, Jessica Lyn, Woody, Neil McIver, Campbell, Shauna Rosalie, Koyfman, Shlomo A., Yilmaz, Emrullah

“…Background Metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) can be treated with immunotherapy (IO). Cranial nerve involvement (CNI) is…”
Get full text

Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002 by Yom, Sue S., Torres-Saavedra, Pedro A., Kuperwasser, Charlotte, Kumar, Sunil, Gupta, Piyush B., Ha, Patrick, Geiger, Jessica Lyn, Banerjee, Robyn, Thorstad, Wade, Blakaj, Dukagjin, Stokes, William A., Sultanem, Khalil, Lang, Pencilla, Lominska, Christopher Erik, Young, Melissa R., Harris, Jonathan, Le, Quynh-Thu

“…6006 Background: NRG-HN002 was a phase II trial that randomized patients with p16-positive oropharynx cancer to 60 Gy IMRT with concurrent cisplatin (IMRT-C)…”
Get full text

CA209-9KY: Results of a phase II study of intensity modulated radiotherapy (IMRT) re-irradiation and concurrent/adjuvant nivolumab (nivo) in patients with loco-regionally recurrent or second primary (RSPT) head and neck squamous cell carcinoma (HNSCC) by Saba, Nabil F., McDonald, Mark William, McCook-Veal, Ashley, Stokes, William A., Nasti, Tahseen, Rudra, Soumon, Bates, James Edward, Remick, Jill, Joshi, Nikhil, Woody, Neil McIver, Geiger, Jessica Lyn, Awan, Musaddiq, Shreenivas, Aditya V., Higgins, Kristin Ann, Steuer, Conor Ernst, Ahmed, Rafi, Shin, Dong Moon, Liu, Yuan, Wong, Stuart J., Koyfman, Shlomo A.

“…6029 Background: RSPT HNSCC within a previously irradiated field presents a technical challenge portending worse outcome. Anti-PD-1 therapy is an approved…”
Get full text

KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma by Geiger, Jessica Lyn, Daniels, Gregory A., Cohen, Ezra E.W., Ge, Joy Yang, Gumuscu, Burak, Swaby, Ramona F., Chang, Anne Lynn S.

“…Abstract only TPS9597 Background: Among patients with high-risk, locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) who receive current…”
Get full text

Single-institute outcomes of palliative chemotherapy in metastatic head and neck squamous cell carcinoma (HNSCC) by Parikh, Rujul H, Fleming, Christopher W, Reddy, Chandana A., Koyfman, Shlomo A., Joshi, Nikhil, Woody, Neil McIver, Burkey, Brian B., Scharpf, Joseph, Lorenz, Robert R, Prendes, Brandon, Ku, Jamie, Lamarre, Eric, Schwartzman, Larisa, Adelstein, David J., Geiger, Jessica Lyn

“…Abstract only e18513 Background: Distantly metastatic HNSCC carries a poor prognosis with limited palliative systemic treatment options and a paucity of…”
Get full text

Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT) by Eziokwu, Akaolisa Samuel, Koyfman, Shlomo A., Reddy, Chandana A., Matia, Brian, Woody, Neil McIver, Joshi, Nikhil Purushottam, Burkey, Brian B., Scharpf, Joseph, Lamarre, Eric, Prendes, Brandon, Lorenz, Robert, Ku, Jamie, Adelstein, David J., Geiger, Jessica Lyn

“…Abstract only e17570 Background: IMRT for HNSCC limits exposure to critical nearby structures thereby reducing toxicities. Real world data on toxicities after…”
Get full text

Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC) by Price, Katharine Andress Rowe, Chintakuntlawar, Ashish V., Foote, Robert Leonard, Garces, Yolanda I., Ma, Daniel, Neben-Wittich, Michelle A., Moore, Eric J., Kasperbauer, Jan C., Price, Daniel L., Janus, Jeffrey R., Van Abel, Kathryn M., Geiger, Jessica Lyn

“…Abstract only 6071 Background: Phase III data suggests a benefit of HDC in the adjuvant setting, but the effect of HDC and WC on long term survival and for…”
Get full text

Selection of patients for surveillance imaging after radiotherapy for squamous cell carcinoma of oral cavity and oropharynx by Zeng, Johnathan, Fleming, Christopher W, Lee, Maxwell, Parikh, Rujul H, Rybicki, Lisa A., Joshi, Nikhil, Woody, Neil McIver, Ku, Jamie, Prendes, Brandon, Lamarre, Eric, Lorenz, Robert R, Scharpf, Joseph, Burkey, Brian B., Chute, Deborah, Schwartzman, Larisa, Geiger, Jessica Lyn, Adelstein, David J., Koyfman, Shlomo A.

“…Abstract only 6533 Background: NCCN guidelines do not recommend routine surveillance imaging for distant failure (DF) after definitive treatment of head & neck…”
Get full text

18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002 by Subramaniam, Rathan M, Demora, Lyudmila, Yao, Min, Yom, Sue S., Gillison, Maura L., Caudell, Jimmy J., Waldron, John, Xia, Ping, Chung, Christine H., Truong, Minh-Tam, Harrison, Louis B, Chan, Jason, Geiger, Jessica Lyn, Mell, Loren, Seaward, Samantha A., Thorstad, Wade, Beitler, Jonathan Jay, Sultanem, Khalil, Blakaj, Dukagjin, Le, Quynh-Thu

“…Abstract only 6563 Background: To determine the negative predictive value (NPV) of 12-14 week post-treatment PET/CT for 2-year progression-free survival (PFS)…”
Get full text

Outcomes of post-operative treatment with concurrent systemic therapy and radiotherapy (RT) in intermediate (INT) risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration by Geiger, Jessica Lyn, Woody, Neil McIver, Tsai, C. Jillian, Ghanem, Ahmed I., Dunlap, Neal, Liu, Howard, Burkey, Brian B., Lamarre, Eric, Ku, Jamie, Scharpf, Joseph, Joshi, Nikhil Purushottam, Caudell, Jimmy J., Siddiqui, Farzan, Porceddu, Sandro, Lee, Nancy Y., Koyfman, Shlomo A., Adelstein, David J.

“…Abstract only e17567 Background: Patients (pts) with adverse pathologic factors in resected OCSCC excluding positive surgical margins or extranodal extension…”
Get full text

Outcomes of postoperative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration by Geiger, Jessica Lyn, Woody, Neil McIver, Tsai, C. Jillian, Ghanem, Ahmed I., Dunlap, Neal, Liu, Howard, Burkey, Brian B., Lamarre, Eric, Ku, Jamie, Scharpf, Joseph, Joshi, Nikhil Purushottam, Caudell, Jimmy J., Siddiqui, Farzan, Porceddu, Sandro, Lee, Nancy Y., Koyfman, Shlomo A., Adelstein, David J.

“…Abstract only 6080 Background: Adjuvant CRT with high-dose cisplatin remains standard treatment for OCSCC with high risk pathologic features of positive…”
Get full text